NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA
NCT05107856 2024-01-31PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesPrelude TherapeuticsPhase 1 Terminated21 enrolled